Page last updated: 2024-09-05

sorafenib and piplartine

sorafenib has been researched along with piplartine in 1 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(piplartine)
Trials
(piplartine)
Recent Studies (post-2010) (piplartine)
6,5207305,2512982261

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)piplartine (IC50)
Signal transducer and activator of transcription 3Homo sapiens (human)7
Thioredoxin reductase 1, cytoplasmicHomo sapiens (human)1.8

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, A; Chen, M; Chen, W; Fang, S; Ji, J; Kong, C; Qiao, E; Shu, G; Weng, Q; Xu, S; Zhang, D; Zhao, Z; Zheng, L1

Other Studies

1 other study(ies) available for sorafenib and piplartine

ArticleYear
Piperlongumine synergistically enhances the antitumour activity of sorafenib by mediating ROS-AMPK activation and targeting CPSF7 in liver cancer.
    Pharmacological research, 2022, Volume: 177

    Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cleavage And Polyadenylation Specificity Factor; Dioxolanes; Humans; Liver Neoplasms; Reactive Oxygen Species; Sorafenib

2022